The insulin syringe market is a fast declining segment. Although the product was once a popular method of injecting insulin, patients have transitioned towards new technologies such as insulin pens and pumps, thereby cannibalizing the insulin syringe segment. Safety insulin syringes are now mainly used in professional healthcare settings, such as hospitals, whereas conventional syringes are no longer used as frequently. Syringe use is still relatively high in Italy due to historical trends, but it is expected that patients will continue to switch to insulin pens and pumps for convenience.
Insulin is a protein and when administered orally, it degrades in the stomach and the intestines. When administered subcutaneously, it is better absorbed and has more of an effect on blood sugar levels. Many alternative technologies have entered the insulin delivery device market, such as insulin pumps and insulin pens, resulting in a fast decline in insulin syringe use across Europe.
Insulin syringes are moving from being hypodermic to those with finer points. Syringes are used with 10 mL insulin vials and come in 0.3 mL, 0.5 mL and 1 mL calibrations. In addition, thinner and shorter syringes are becoming more popular in the market, as they cause less discomfort when giving an injection. Needle thickness is indicated by gauge number; the higher the gauge number, the thinner the needle.
'
TABLE OF CONTENTS I
LIST OF FIGURES IV
LIST OF CHARTS V
EXECUTIVE SUMMARY 1
EUROPEAN MARKET FOR DIABETES MONITORING, TREATMENT AND DRUG DELIVERY 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 6
MARKET DEVELOPMENTS 8
MARKETS INCLUDED 9
KEY REPORT UPDATES 10
VERSION HISTORY 10
RESEARCH METHODOLOGY 11
1.1 RESEARCH SCOPE 11
1.2 IDATA’S 9-STEP METHODOLOGY 11
Step 1: Project Initiation & Team Selection 11
Step 2: Prepare Data Systems and Perform Secondary Research 13
Step 3: Preparation for Interviews & Questionnaire Design 14
Step 4: Performing Primary Research 15
Step 5: Research Analysis: Establishing Baseline Estimates 17
Step 6: Market Forecast and Analysis 18
Step 7: Identify Strategic Opportunities 20
Step 8: Final Review and Market Release 21
Step 9: Customer Feedback and Market Monitoring 22
DISEASE OVERVIEW 23
2.1 INTRODUCTION 23
2.1.1 Types of Diabetes 23
2.1.2 Diabetes Complications 25
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 27
2.1.4 Signs and Symptoms 28
2.1.5 Diabetes Monitoring 29
2.1.6 Treatment 31
2.1.7 Drug Delivery Systems 33
COUNTRY PROFILES 35
3.1 INTRODUCTION 35
3.1.1.1 Population 35
3.1.1.2 GDP Per Capita 35
3.1.1.3 Units 35
3.2 GERMANY 36
3.3 FRANCE 37
3.4 UNITED KINGDOM 38
3.5 ITALY 39
3.6 SPAIN 40
3.7 BENELUX 41
3.8 SCANDINAVIA 42
3.9 AUSTRIA 43
3.10 SWITZERLAND 44
3.11 PORTUGAL 45
INSULIN SYRINGE MARKET 46
4.1 INTRODUCTION 46
4.2 MARKET ANALYSIS AND FORECAST 47
4.3 DRIVERS AND LIMITERS 54
4.3.1 Market Drivers 54
4.3.2 Market Limiters 54
4.4 COMPETITIVE MARKET SHARE ANALYSIS 56
ABBREVIATIONS 60
Chart 1 1: Diabetes Diagnosis, Treatment and Drug Delivery, Europe, 2012 – 2022 3
Chart 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Market Overview, Europe, 2012 & 2022 3
Chart 3 1: Country Profile, Germany, 2015 36
Chart 3 2: Country Profile, France, 2015 37
Chart 3 3: Country Profile, United Kingdom, 2015 38
Chart 3 4: Country Profile, Italy, 2015 39
Chart 3 5: Country Profile, Spain, 2015 40
Chart 3 6: Country Profile, Benelux, 2015 41
Chart 3 7: Country Profile, Scandinavia, 2015 42
Chart 3 8: Country Profile, Austria, 2015 43
Chart 3 9: Country Profile, Switzerland, 2015 44
Chart 3 10: Country Profile, Portugal, 2015 45
Chart 4 1: Total Insulin Syringe Market, Europe, 2012 – 2022 48
Chart 4 2: Leading Competitors, Insulin Syringe Market, Europe, 2015 59
Figure 1 1: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (1 of 2) 4
Figure 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (2 of 2) 4
Figure 1 3: Companies Researched in this Report, Europe, 2015 5
Figure 1 4: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (1 of 2) 6
Figure 1 5: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (2 of 2) 7
Figure 1 6: Recent Events in the Diabetes Diagnosis, Treatment and Drug Delivery Market, Europe, 2012 – 2016 8
Figure 2 1: Major Types of Diabetes and Related Pathologies, Europe, 2015 24
Figure 2 2: Risk Factors Associated with Type 1 and Type 2 Diabetes, Europe, 2015 28
Figure 2 3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes, Europe, 2015 29
Figure 4 1: Total Insulin Syringe Market, Europe, 2012 – 2022 (€ and US$) 47
Figure 4 2: Units Sold (Millions) by Country, Total Insulin Syringe Market, Europe, 2012-2022 49
Figure 4 3: Average Sales Price by Country, Total Insulin Syringe Market, Europe, 2012-2022 (€) 50
Figure 4 4: Average Sales Price by Country, Total Insulin Syringe Market, Europe, 2012-2022 (US$) 51
Figure 4 5: Total Insulin Syringe Market by Country, Europe, 2012-2022 (€M) 52
Figure 4 6: Total Insulin Syringe Market by Country, Europe, 2012-2022 (US$M) 53
Figure 4 7: Drivers and Limiters, Insulin Syringe Market, Europe, 2015 55
Figure 4 8: Leading Competitors, Insulin Syringe Market, Europe, 2015 58
Novo Nordisk
Sanofi
Roche
Johnson & Johnson
Eli Lilly
Abbott
Ascensia
Becton Dickinson
Medtronic
Menarini
DexCom
Ypsomed
Insulet
Artsana
B. Braun
Terumo
Others include: Abbott, AgaMatrix, Artsana, Apollo, BBI Healthcare, B. Braun, Berger, Beurer, Boehringer Ingelheim, Cellnovo, Codan, Comfort Point, Dario Health, Elektronika, Entra Health Systems, GlucoRx, GlucoZen, Infopia, Medtronic, MED TRUST, Medisana, Menarini, Merck Serono, MSP bodmann, Neon Diagnostics, NordicInfu Care, Novalab Ibérica, Novico, Owen Mumford, Pentaferte, Roche, Sanofi, SD BIOSENSOR, SFM Medical, Smiths Medical, Spirit Healthcare, Sooil, Trividia Health, Ypsomed, etc.
